Trytosaveabit
reacted to and commented on
$AIM ImmunoTech (AIM.US)$
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP
by Globe Newswire
Follow
Company to participate in Live Virtual Investor Closing Bell segment today, April 16th at 4:00 PM ET; Register for the event here
OCALA, Fla., April 16, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today highlighted ac...
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP
by Globe Newswire
Follow
Company to participate in Live Virtual Investor Closing Bell segment today, April 16th at 4:00 PM ET; Register for the event here
OCALA, Fla., April 16, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today highlighted ac...
3
3
$Performance Shipping (PSHG.US)$ Performance Shipping Secures 7-Year Time Charter With Repsol Trading For Suezmax Tanker Newbuilding Vessel At $35K/Day, 5-Year Time Charter At $36,850K/Day, Commencing October 2028, May 2029, Respectively
Benzinga
2m
Performance Shipping Inc. (NASDAQ:PSHG), ("we" or the "Company"), a global shipping company specializing in the ownership of tanker vessels, today announced that it has entered into time charter agreements with Repsol Trading S.A. ("Repsol") for i...
Benzinga
2m
Performance Shipping Inc. (NASDAQ:PSHG), ("we" or the "Company"), a global shipping company specializing in the ownership of tanker vessels, today announced that it has entered into time charter agreements with Repsol Trading S.A. ("Repsol") for i...
1
$Myriad Genetics (MYGN.US)$ Will share six abstracts, including two podium presentations, at the American Association for Cancer Research (AACR) Annual Meeting 2026.
The company will share new results from the MONITOR-Breast study, a prospective, multi-center clinical trial evaluating the performance of Precise MRDTM in breast cancer across all phases of the treatment journey. The data will be shared in a podi...
The company will share new results from the MONITOR-Breast study, a prospective, multi-center clinical trial evaluating the performance of Precise MRDTM in breast cancer across all phases of the treatment journey. The data will be shared in a podi...
8
1
Trytosaveabit
commented on
$Momentus (MNTS.US)$ Reuters
5m
Momentus Announces Closing of $5 Million Private Placement of Common Stock Priced at-the-Market Under Nasdaq Rules With a New Fundamental Institutional Investor
5m
Momentus Announces Closing of $5 Million Private Placement of Common Stock Priced at-the-Market Under Nasdaq Rules With a New Fundamental Institutional Investor
2
6
Trytosaveabit
reacted to and commented on
1
1
Trytosaveabit
reacted to and commented on
$Achieve Life (ACHV.US)$
Achieve Life Sciences Announces Up to $354 Million Private Placement
by Globe Newswire
Follow
$180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA Approval
Transaction led by Frazier Life Sciences, TPG Life Sciences Innovations, venBio Partners, Paradigm BioCapital Advisors and Marshall Wace
SEATTLE, Wash. and VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, In...
Achieve Life Sciences Announces Up to $354 Million Private Placement
by Globe Newswire
Follow
$180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA Approval
Transaction led by Frazier Life Sciences, TPG Life Sciences Innovations, venBio Partners, Paradigm BioCapital Advisors and Marshall Wace
SEATTLE, Wash. and VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, In...
1
1
$Achieve Life (ACHV.US)$ Achieve Life Sciences Announces Up to $354M Private Placement! $180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA Approval
Dow Jones
1m
Dow Jones
1m
3
Trytosaveabit
commented on
$INmune Bio (INMB.US)$ Reuters
3m
INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating Inb03 (Xpro1595) Overcomes Resistance and Reduces Metastases in Her2-Positive Breast Cancer Models
3m
INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating Inb03 (Xpro1595) Overcomes Resistance and Reduces Metastases in Her2-Positive Breast Cancer Models
3
13
Trytosaveabit
reacted to and commented on
$SRx Health Solutions (SRXH.US)$ Press Release: SRx Health Solutions Acquires Shares of Compass Inc. and Increases Investment in Opendoor Technologies Inc.
1
4
Trytosaveabit
commented on
$Allied Gaming & Entertainment (AGAE.US)$ Allied Gaming & Entertainment Inc - Board Does Not Expect to Approve Future M&a Share Issuances Below $2.00 per Share
7
![[empty]](https://static.moomoo.com/node_futunn_nnq/assets/images/folder.5c37692712.png)
![[error]](https://static.moomoo.com/node_futunn_nnq/assets/images/no-network.991ae8055c.png)
Trytosaveabit : Hey Brother have not decided if im going wide with this? But wanted you to know in case you missed it. My notes say that they are expected to release the next DURIPANC update in June 2026. Reason im not sure about sharing as a “Heads-Up” Might be a bit petty? Hehehe But starting to really feel taken for ganted. Like i had a person ask for lvls on Monday on a trade i was already out of! But i went ahead and gave them. All hit except the final lvl and that only missed by 0.04! No thanks, no good job, not a peep! Then yesterday was asked for info on another ticker. I gave what i had and they said “Oh no i meant FDA not data release” So i then answered in depth about the upcoming FDA! And guess what? Hehehe Not a Thanks or cool I appreciate it! Nothing! Hehehe So yes i guess im being a bit petty but a lil appreciation can go a long way! Hehehe